Loading clinical trials...
Loading clinical trials...
A Phase 1b, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics of Sapu003 in Advanced mTOR-sensitive Solid Tumors (With or Without Exemestane)
Conditions
Interventions
Sapu003
Exemestane 25 MG
Locations
1
Australia
SOCRU
Adelaide, Australia
Start Date
December 15, 2025
Primary Completion Date
June 1, 2026
Completion Date
December 1, 2026
Last Updated
January 27, 2026
NCT03206060
NCT07536087
NCT07117227
NCT05735080
NCT06228066
NCT05746208
Lead Sponsor
SAPU NANO (US) LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions